^
Association details:
| Biomarker: | ARID1A K1238fs + FGFR2 R210Q |
|---|---|
| Cancer: | Lung Cancer |
| Drug: | Vitrakvi (larotrectinib) (TrkB receptor inhibitor, TrkC kinase inhibitor, TrkA receptor inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Updated efficacy and ctDNA analysis of patients with TRK fusion lung cancer treated with larotrectinib
Published date:
03/23/2022
Excerpt:
ctDNA datawere available for 14 evaluable pts; 13 in which somatic alterations were detected. ctDNA analysis detected NTRK gene fusions in 46% of the pts at treatment start. Bythe data cut-off, 6 pts had a progression event with ctDNA data available for 5 pts. Potential acquired mutations were identified in 3 pts: one with NTRK1 F589L and G595R, one with SMAD4 R361C and the third with ARID1A K1238fs and FGFR2 R210Q mutations.
Trial ID:
Test:
